MTEM Molecular Templates Inc

EDISON EQUITY RESEARCH: THRESHOLD PHARMACEUTICALS - PIVOTAL STS PHASE III CONTINUES AS PLANNED

The conclusion of the interim efficacy and safety analysis of Threshold’s ongoing Phase III soft tissue sarcoma (STS) trial is for the study to continue as planned, in line with both our and management’s expectations. Based on the current event rate, the number of events (n=434 deaths) required for the primary efficacy analysis are expected to be reached in H215. STS could be the first approved indication for TH-302.

Threshold Pharmaceuticals is a US oncology company focused on tumour hypoxia, a low-oxygen condition found in most solid tumours and some blood cancers. TH-302 is in Phase III for STS and pancreatic cancer, in addition to trials in multiple other cancers and is partnered with Merck KGaA.

To view our full report, please click here:
http://www.edisoninvestmentresearch.com/research/report/threshold-pharmaceuticals8

Click here to view all of Edison Investment Research’s published reports